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1 |  INTRODUCTION
Parkinson's disease (PD) is a complex age-related neurode-
generative disease, affecting about 1–2 out of 1,000 people 
worldwide (Tysnes & Storstein, 2017). It is mainly charac-
terised by a set of motor symptoms, including resting tremor, 
muscular rigidity, bradykinesia and difficulty with move-
ment initiation (Kalia & Lang, 2015). These main symptoms 
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Parkinson's disease (PD) is characterised by selective and severe degeneration of the 
substantia nigra pars compacta and the locus coeruleus (LC), which underlies the 
most prominent symptoms. Although α-synuclein accumulation has long been estab-
lished to play a causal role in the disease, it alone cannot explain the selective degen-
erative pattern. Recent evidence shows that the selective vulnerability could arise due 
to the large presence of cytosolic catecholamines and Ca2+ ions in the substantia nigra 
pars compacta and LC specifically that can be aberrantly affected by α-synuclein 
accumulation. Moreover, each has its own toxic potential, and disturbance of one 
can exacerbate the toxic effects of the others. This presents a mechanism unique to 
these areas that can lead to a vicious degenerative cycle. Interestingly, in familial 
variants of PD, the exact same brain areas are affected, implying the underlying 
process is likely the same. However, the exact disease mechanisms of many of these 
genetic variants remain unclear. Here, we review the effects of the PD-related genes 
Parkin, PINK1 and DJ-1. We establish that these mutant varieties can set in motion 
the same degenerative process involving α-synuclein, cytosolic catecholamines and 
Ca2+. Additionally, we show indications that model organisms might not accurately 
represent all components of this central mechanism, explaining why Parkin, PINK1 
and DJ-1 model organisms often lack a convincing PD-like phenotype.
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arise due to progressive degeneration of dopaminergic neu-
rons within the substantia nigra pars compacta (SNc). Loss 
of these dopaminergic neurons leads to a decreased dopa-
mine output within the basal ganglia, causing an imbalance 
between the direct and indirect pathways in the basal gan-
glia–thalamo–cortical motor loop that underlies the motor 
symptoms (Blandini, Nappi, Tassorelli, & Martignoni, 2000; 
Przedborski, 2017). It is largely unknown what triggers the 
disease, although PD is thought to start years or even de-
cades before the appearance of motor symptoms. By this 
time though, massive neuronal loss in the SNc has already 
occurred. Definitive diagnosis can generally only be made 
post-mortem, through examination of the brain tissue. There 
are several non-motor symptoms associated with PD, some of 
which precede the motor symptoms. These include sleep dis-
turbance, constipation, mood swings and olfactory deficits. 
However, these are too unspecific for diagnostic use (Visanji 
& Marras, 2015). Late-stage disease is often accompanied by 
cognitive decline and dementia (Kalia & Lang, 2015).
There is currently no treatment available to halt disease 
progression. The few treatments in use are aimed at symp-
tom alleviation and improving the quality of life. The most 
common is l-Dopa, a precursor to dopamine that can cross 
the blood–brain barrier, which, following uptake into dopa-
minergic neurons and conversion to dopamine, supplements 
the dopamine shortage. At later disease stages, when even 
more of the SNc has been lost, this treatment becomes inef-
fective. Deep brain stimulation is also used in some cases to 
restore balance to the basal ganglia–thalamo–cortical motor 
loop by inhibiting the subthalamic nucleus, normalising the 
system's output. This therapeutic measure deals with the con-
sequences of the dopamine shortage instead of the shortage 
itself; however, it also alleviates the motor symptoms and 
does not halt disease progression.
Parkinson's disease is thus a multifactorial disease, com-
prising both genetic and environmental risk factors. About 
90% of all cases are sporadic, with no determined underlying 
cause. The remaining 10% of PD cases have been linked to 
predisposing genes that can be inherited either in an autoso-
mal dominant or recessive manner (Klein & Westenberger, 
2012). The first familial variant of PD was discovered in 
1997, with a mutation of the SNCA gene, which encodes 
alpha-synuclein (α-syn) (Polymeropoulos et al., 1997). This 
was a promising discovery, as sporadic PD coincides with 
progressive intraneuronal accumulation of α-syn, forming 
protein aggregates named Lewy bodies throughout the cen-
tral nervous system (CNS). These findings suggest a causal 
role for α-syn in the degenerative process. Moreover, a trip-
lication of wild-type α-syn has also been related to familial 
PD (Singleton et al., 2003), establishing that overexpressing 
regular α-syn is sufficient to initiate aggregation and cause 
disease. Furthermore, this implies a causal role for α-syn in 
the degenerative process through a toxic gain-of-function 
mechanism that underlies neuronal death, but what triggers 
this aggregation in sporadic PD remains elusive.
In recent years, many more disease genes have been iden-
tified that encode proteins that seem to be working in many 
different pathways and have a myriad of functions, though all 
underlying a similar disease phenotype. This sparked discus-
sion whether PD can be considered one disease or more like 
a syndrome comprised of a multiple of diseases with a sim-
ilar phenotype, which may have implications for treatment. 
However, the distinction between sporadic PD and hereditary 
forms is not always clear-cut. Familial varieties often do not 
have complete penetrance, and sporadic PD patients often do 
possess some genetic risk factors that include mutations in 
genes related to familial PD (Schulte & Gasser, 2011). As 
genetic and sporadic PD share certain characteristics, mainly 
the specific degeneration of the SNc and locus coeruleus 
(LC) often accompanied by Lewy bodies, the mechanism 
underlying the most prominent disease symptoms may very 
well be the same. Recently, the aberrant interactions between 
α-syn and catecholamines have been pointed out as a poten-
tial mechanism for the specific degeneration seen in PD (Post, 
Lieberman, & Mosharov, 2018). This review will discuss 
how several familial variants of PD may directly facilitate 
these same aberrant interactions in the specific brain areas 
involved, providing an explanation for the similar phenotypes 
of sporadic and familial PD. Identifying such a common 
mechanism would prove very valuable in terms of potential 
therapies, especially in these familial varieties where early 
diagnosis is possible.
2 |  SPORADIC PARKINSON'S 
DISEASE AND ALPHA-SYNUCLEIN
α-syn is believed to play a causal role in the neurodegen-
eration seen in PD. It is the primary constituent of Lewy 
bodies, the protein aggregates accompanying both sporadic 
PD and most cases of familial PD. Despite it being a high 
interest topic due to its implications in the disease, surpris-
ingly little is known about its exact endogenous functions. 
α-syn is a small, 140 amino acid, evolutionarily conserved 
protein that is specific to vertebrates (Jakes, Spillantini, & 
Goedert, 1994; Mor, Ugras, Daniels, & Ischiropoulos, 2016). 
It consists of three domains: an N-terminal lipid-binding do-
main, an amyloid binding domain and a C-terminal acidic tail 
(Emamzadeh, 2016). Indeed, α-syn often associates with lipid 
membranes, primarily interacting with membranes with high 
curvature, like pre-synaptic vesicles. Coincidentally, α-syn is 
largely localised to the pre-synaptic nerve terminal, where 
it is believed to play a part in neurotransmitter handling and 
release (Logan, Bendor, Toupin, Thorn, & Edwards, 2017). It 
has been shown to promote both vesicle retention in the pre-
synaptic vesicle pool and neurotransmitter release by aiding 
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in the SNARE complex-mediated fusion of the vesicle with 
the pre-synaptic membrane (Bendor, Logan, & Edwards, 
2013; Burré, Sharma, & Südhof, 2014; Emamzadeh, 2016). 
Upon interaction with membranes, the N-terminal adopts an 
alpha helix structure (Emamzadeh, 2016). In contrast, α-syn 
is a natively largely unstructured protein when localised to 
the cytosol. These cytosolic, unstructured monomers are 
more prone to aggregate (Mor et al., 2016).
It is most likely that α-syn mediates neurodegeneration 
mainly via a toxic gain-of-function mechanism. A loss of 
function seems an unlikely major contributor as α-syn KO 
mice show no symptoms or signs of neurodegeneration. In 
part, this was attributed to functional redundancy between 
α-syn and the closely related β- and γ-synuclein. However, 
even a triple KO for all synucleins, albeit having some be-
havioural abnormalities and alterations in neurotransmitter 
handling, showed no signs of neurodegeneration (Anwar et 
al., 2011). In contrast, experimental overexpression of α-syn 
causes it to aggregate and lead to cell death, which is similar 
to what is seen in the familial form of PD caused by SNCA 
gene multiplication. Moreover, several point mutations have 
been found within the SNCA gene that all lead to autoso-
mal dominant forms of PD: A30P, E46K, H50Q, G51D and 
A53T. Interestingly, these mutations are clustered in the lip-
id-binding domain of α-syn, affecting its alpha helix structure 
and lipid affinity. Although they do not behave exactly the 
same in every respect, the A30P, H50Q and A53T mutants do 
have in common that they are more unstructured and have an 
increased propensity to form protofibrils (Narhi et al., 1999; 
Rutherford, Moore, Golde, & Giasson, 2014). This supports 
that aggregation of α-syn likely plays an important role in PD 
in general, although there may be other factors at play as well. 
Additionally, α-syn is a vertebrate-specific protein, but it can 
aggregate and mediate specific dopaminergic neurodegenera-
tion in non-vertebrate organisms like Drosophila melanogas-
ter when experimentally expressed (Feany & Bender, 2000). 
The dominant manner of inheritance of SNCA-related PD 
combined with an intrinsic propensity to aggregate and caus-
ing cell death supports a toxic gain-of-function mechanism.
The coincidental appearance of Lewy bodies in PD and 
the toxic properties of aggregating α-syn indicate that Lewy 
bodies may play a causal role. Indeed, large aggregates can 
interfere with cellular processes due to their size. However, 
aggregation into large aggregates might not be the most 
harmful aspect of α-syn aggregation. Smaller, soluble, oligo-
meric species that generate early on in the aggregation pro-
cess likely possess the most detrimental properties (Winner 
et al., 2011). α-syn oligomers exert their toxic effects by 
interfering with SNARE complex formation and disrupting 
membranes, making them more permeable (van Rooijen, 
Claessens, & Subramaniam, 2010; Winner et al., 2011). This 
subsequently affects calcium (Ca2+) regulation (Danzer et al., 
2007), pre-synaptic vesicle integrity, neurotransmitter release 
and mitochondrial function, which are all suspected to be in-
volved in PD pathology. Therefore, favouring large, stable 
aggregates minimises exposure to these oligomers. Although 
aggregates themselves are harmful as well, they are likely 
a lesser of evils when compared to their small oligomeric 
counterparts.
Most neurodegenerative diseases, including PD, are as-
sociated with pathogenic protein aggregation that starts later 
in life. There are protein quality control (PQC) systems in 
place within the cell that guard the protein homeostasis and 
can prevent protein aggregation (Martinez-Vicente, Sovak, 
& Cuervo, 2005). Chaperone proteins regulate correct pro-
tein folding and work closely together with clearance mech-
anisms dedicated to degrading misfolded, damaged and 
even aggregated proteins (Hartl, Bracher, & Hayer-Hartl, 
2011). The main mechanism by which α-syn is degraded is 
chaperone-mediated autophagy (CMA) (Vogiatzi, Xilouri, 
Vekrellis, & Stefanis, 2008), although the ubiquitin–pro-
teasome system is also involved in regulating α-syn levels 
(Webb, Ravikumar, Atkins, Skepper, & Rubinsztein, 2003). 
The CMA substrate is transported to lysosomes. There, the 
substrate is recognised by LAMP2A, the lysosomal recep-
tor responsible for transporting CMA substrates into the 
lysosomal lumen for degradation. The PQC mechanisms, in-
cluding CMA, are known to decline with age, making cells 
more susceptible to pathogenic protein accumulation (Hartl 
et al., 2011). Additionally, the amount of damaged proteins 
increases with age due to accumulation of somatic mutations 
in the DNA, as well as increased damage to proteins them-
selves caused by higher amounts of reactive oxygen species 
(ROS) due to age-related decrease in mitochondrial function 
(Krisko & Radman, 2019). This puts increasing pressure on a 
declining PQC system, allowing aggregation-prone proteins 
to escape this system, which explains why most protein ag-
gregation-associated neurodegenerative diseases arise at a 
later age (Martinez-Vicente et al., 2005).
α-syn pathology is not strictly cell autonomous, and ag-
gregation-prone α-syn may spread from neuron to neuron. 
PD patients who have received grafted embryonic stem 
cells to replace lost dopaminergic neurons had Lewy bod-
ies present within these cells upon post-mortem tissue ex-
amination (Li et al., 2008). Mouse models later provided 
evidence that α-syn accumulation can spread through-
out the brain in a prion-like manner (Bernis et al., 2015; 
Planchard, Exley, Morgan, & Rangachari, 2014; Reidy, 
Sharma, Roberts, & Masison, 2016). Interestingly, Braak 
and colleagues have reported that, in sporadic PD cases, 
α-syn accumulation spreads through the CNS in a specific 
manner. It first shows up in the enteric nervous system and 
the olfactory bulb. It then moves up the vagus nerve to the 
brainstem, subsequently to the basal ganglia, the SNc and 
LC, and lastly spreading through the cortex (Braak et al., 
2003). Interestingly, this pattern correlates to some of the 
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pre-motor symptoms and the late-stage dementia. However, 
the SNc and LC are reached relatively late by this spread of 
pathological α-syn.
3 |  SELECTIVE VULNERABILITY
As PD progresses, α-syn pathology will spread through 
most of the CNS and affect many brain areas. However, 
the pattern of α-syn accumulation does not correlate well 
with neuronal cell death (Braak et al., 2003). The SNc and 
the LC degenerate early on, compared to other degenerat-
ing areas, and much more severely, despite being reached 
by α-syn pathology relatively late. It has been suggested 
that these dopaminergic neurons may be more vulnerable 
because they are large, lack myelin and have a higher en-
ergy requirement than other neurons (Bolam & Pissadaki, 
2012; Foomt, 1985), resulting in more ROS production and 
related damage. However, this does not explain why these 
areas are so vulnerable in PD specifically. Moreover, do-
paminergic neurons in the ventral tegmental area (VTA), 
for example, are relatively spared, despite sharing most 
of their characteristics with the SNc. The common fac-
tor of the SNc and the LC, which is also specific to these 
areas, is that they both accumulate neuromelanin with age. 
Neuromelanin is a pigment that gives these areas their 
characteristic dark colour, after which they are named. 
Interestingly, neuromelanin mainly consists of iron mol-
ecules in conjunction with oxidised catecholamine deriva-
tives native to the respective area, enveloped in a double 
membrane of autophagic origin (Sulzer et al., 2000; Zucca 
et al., 2018). Coincidentally, the SNc and LC have elevated 
levels of cytosolic catecholamines when compared to other 
catecholaminergic areas. Cytosolic catecholamines can 
be toxic at a neutral pH, where they can auto-oxidise and 
cause damage to the cell. For the mechanisms, this review 
will focus mostly on the SNc and dopamine, as there are 
more data available about this area due to its direct link to 
the motor symptoms of PD, though it is likely that the LC 
is subjected to similar processes.
After production, dopamine is immediately stored in 
pre-synaptic vesicles by the vesicular dopamine transporter 
VMAT2. Due to coinciding proton transport required for 
transporter activity, the vesicle lumen has a low pH value at 
which dopamine is stable and does not auto-oxidise. Tyrosine 
hydroxylase (TH) and l-amino acid decarboxylase (AADC) 
have been found to associate with VMAT2, likely to promote 
dopamine storage in vesicles and limit its presence in the cy-
tosol (Cartier et al., 2010). Given that dopaminergic neurons 
of the SNc have higher cytosolic dopamine levels compared 
to other dopaminergic areas, it makes them more susceptible 
to dopamine oxidation and its toxic consequences. At a neu-
tral pH, dopamine can spontaneously react with oxygen by do-
nating electrons from its O− groups to free oxygen molecules. 
This results in the formation of dopamine quinones and cre-
ates ROS in the process. Dopamine quinones stabilise in the 
form of aminochrome (Table 1; Muñoz, Huenchuguala, Paris, 
& Segura-Aguilar, 2012). While high amounts of ROS are 
damaging on their own, aminochrome can form adducts with 
several proteins implicated in PD, including Parkin (LaVoie, 
Ostaszewski, Weihofen, Schlossmacher, & Selkoe, 2005), DAT 
(Whitehead, Ferrer, Javitch, & Justice, 2001) and perhaps, most 
interestingly, α-syn (Chen & Saez-Atienzar, 2018; Muñoz et 
al., 2012). Dopaminergic neurons have mechanisms in place to 
prevent aminochrome formation, including TH feedback inhi-
bition (Dickson & Briggs, 2013), VMAT2-mediated storage in 
vesicles and neuromelanin formation. Indeed, neuromelanin is 
likely a protective mechanism to sequester reactive dopamine 
forms to prevent aberrant interactions in the cytosol. This is 
supported by the fact that neuromelanin is absent at birth and 
accumulates with age. Neuromelanin formation under normal 
conditions is almost exclusively seen in humans (Fedorow et 
T A B L E  1  Structures of dopamine 
and dopamine quinones. In a low pH 
environment, dopamine is stable, whereas in 
a neutral pH environment like the cytosol, 
it can donate electrons and form dopamine 
quinones, generating reactive oxygen 
species (ROS) in the process
Name: Structure:
Dopamine (low pH environment)
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al., 2005). However, it can be induced in animal models and cell 
models in which neuromelanin is normally absent by supple-
menting them with l-Dopa, further establishing neuromelanin 
as a storage mechanism for excess dopamine. This effect can be 
rescued by overexpression of VMAT2, indicating that it is in-
deed a consequence of high cytosolic dopamine content (Sulzer 
et al., 2000).
Although the human SNc has high levels of cytosolic 
dopamine, this alone is not sufficient to cause neurodegen-
eration. However, there is evidence that aggregating α-syn 
and cytosolic dopamine can both exacerbate each other's 
pathogenic properties (Post et al., 2018). Dopamine qui-
nones can stabilise α-syn oligomers and inhibit aggregate 
formation. This causes an accumulation of toxic oligomers 
that subsequently lead to more vesicle damage, causing 
more dopamine to leak into the cytosol (Conway, Rochet, 
Bieganski, & Lansbury, 2001). Additionally, dopamine qui-
nones can interact with α-syn monomers, forming adducts 
that block LAMP2A and thus CMA. They do so by inter-
acting with LAMP2A, but LAMP2A is not able to transport 
these adducts to the lysosomal lumen, effectively block-
ing this transporter (Martinez-Vicente et al., 2008). The 
A30P and A53T familial SNCA mutants also block CMA 
in a similar manner (Cuervo, Wong, & Martinez-Vicente, 
2010; Post et al., 2018). As α-syn degradation is largely 
dependent on CMA, it can block its own degradation in 
the presence of cytosolic dopamine. This can cause an in-
crease of α-syn levels and consequentially its propensity to 
aggregate. While overexpression of α-syn is most toxic in 
neurons with relatively high cytosolic dopamine content, 
the opposite is also true. VMAT2-KD mice have increased 
cytosolic dopamine levels; however, this only causes de-
generation when α-syn is present as well, and not in α-syn 
KO mice. VMAT2-KD mice with endogenous α-syn also 
showed Lewy body accumulation, indicating that increased 
cytosolic dopamine alone can trigger α-syn aggregation 
at normal α-syn levels (van der Putten et al., 2000). This 
shows that elevating either α-syn or cytosolic dopamine 
levels, with the other present at normal levels, can lead to 
α-syn aggregation.
Another common factor of the SNc and LC is that they have 
high Ca2+ content, due to their intrinsic pacemaking activity. 
Ca2+ positively regulates catecholamine production (Mosharov 
et al., 2009), which may contribute to the high catecholamine 
levels in these areas. Moreover, these areas lack calbindin that 
binds free Ca2+, while calbindin is present in dopaminergic 
neurons like the VTA that are relatively spared in PD (Dauer 
& Przedborski, 2003). Ca2+ is normally translocated to the mi-
tochondrial lumen because of the negative charge generated by 
proton pump activity. However, additional Ca2+ can leak into 
the cell through α-syn oligomer-mediated permeabilisation 
of the cell membrane and lysosomal membranes (Bourdenx, 
Bezard, & Dehay, 2014; Post et al., 2018). High cytosolic Ca2+ 
levels may contribute to increased catecholamine production 
(Mosharov et al., 2009) and α-syn aggregation (Rcom-H’cheo-
Gauthier, Goodwin, & Pountney, 2014), in addition to being 
toxic in itself (Orrenius & Nicotera, 1994).
Taken together, the interactions of α-syn, dopamine 
and Ca2+ provide a mechanism that can set in motion a vi-
cious cycle of toxicity leading to degeneration (Figure 1). 
Moreover, the SNc and LC provide the perfect conditions for 
such a process due to their high cytosolic dopamine and Ca2+ 
content. More importantly, this mechanism can lead to the 
same pathological process, regardless of which component 
triggered it. While familial PD genes are seemingly involved 
in different processes, it could be that they connect to differ-
ent parts of this central mechanism and subsequently cause a 
highly similar degenerative phenotype.
4 |  FAMILIAL PD—PARKIN AND 
PINK1
There are many gene variants known to be associated with 
familial PD. Several are heritable in an autosomal dominant 
manner, including mutations in SNCA, LRRK2 and VPS35, 
which all cause late-onset PD very similar to sporadic PD. 
Others, namely Parkin, PINK1 and DJ-1, are heritable in an 
autosomal recessive manner and result in early-onset PD 
(Klein & Westenberger, 2012; Schulte & Gasser, 2011). 
Many of the PD genes have a myriad of functions and are 
expressed throughout the CNS or even beyond. Yet, their 
PD-associated mutant varieties lead to the same character-
istic degeneration of the SNc and LC as seen in sporadic 
PD. Additionally, the line between sporadic PD and familial 
PD can be blurry in certain cases. Heterozygosity for reces-
sive variants is a risk factor for sporadic PD, and dominant 
variants never have complete penetrance (Schulte & Gasser, 
2011). The recessive PD variants Parkin, PINK1 and DJ-1 
are interesting for finding a common mechanism linking 
sporadic and familial PD because homozygotes have 100% 
penetrance combined with an early disease onset (Schulte & 
Gasser, 2011). If there is a connection to aberrant α-syn–do-
pamine interactions, it must be most clear in these because of 
this severe phenotype.
Parkin is encoded by the PARK2 gene, and mutations 
in this gene are known to cause recessive, early-onset PD 
(Lücking et al., 2000), where degeneration can occasionally 
be accompanied by Lewy bodies. Parkin is an E3 ubiquitin 
ligase and a component of the PQC system, responsible for 
tagging to be degraded proteins with ubiquitin, which marks 
them for degradation. There is a large amount of E3 ligases 
that have their own set of substrates, which provides specific-
ity to the degradation system. Parkin is a ubiquitous protein, 
but expression is relatively high in the CNS. PD-associated 
mutations are spread throughout the whole gene and include 
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truncations, pointing towards a loss of function being respon-
sible for the PD phenotype. Several Parkin KO models have 
been developed to help identify a neurodegenerative mecha-
nism; however, results remain inconsistent and species-de-
pendent. In Drosophila melanogaster, Parkin depletion 
mediated degeneration of the flight muscles, accompanied by 
mitochondrial damage (Greene et al., 2003). Mouse models 
showed no clear phenotype but did show behavioural changes 
(Goldberg et al., 2003) and a general increased cellular sen-
sitivity to apoptosis (Casarejos et al., 2006). Cell models 
showed morphological changes to mitochondria accompa-
nied by excessive ROS production (Narendra, Tanaka, Suen, 
& Youle, 2008; Pickrell & Youle, 2015).
Mitochondrial dysfunction and ROS-related damage 
had previously been associated with sporadic PD (Schapira 
et al., 1990). Later research suggested the involvement of 
α-syn, which can be imported into mitochondria where it 
blocks complex 1 of the mitochondrial respiration chain, 
leading to mitochondrial depolarisation and ROS production 
(Martínez et al., 2018; Reeve et al., 2015). This sparked the 
idea that mitochondrial deficits may play a causal role in PD. 
Interestingly, Parkin was found to be involved in mitophagy, 
the clearance of mitochondria through macro-autophagy. 
Moreover, the signalling pathway regulating this process 
also includes PINK1, another gene involved in familial PD 
(Pickrell & Youle, 2015). Coincidentally, PINK1 mutations 
also cause recessive, early-onset PD, which is generally 
associated with Lewy bodies (Maria Valente et al., 2004). 
Experimentally, a PINK1 KO can be rescued through Parkin 
overexpression, whereas a Parkin KO cannot be rescued by 
PINK1 overexpression, indicating that PINK1 functions up-
stream of Parkin. Aged or damaged mitochondria lose their 
membrane potential, which causes PINK1 to translocate to the 
outer mitochondrial membrane. Here, PINK1 recruits Parkin 
and mediates its activation by phosphorylation of Parkin, re-
lieving Parkin's auto-inhibited state in which it is normally 
present. Parkin then mediates clustering of these mitochon-
dria and subsequent clearance via mitophagy (Matsuda et al., 
2010; Pickrell & Youle, 2015). PD-associated mutations in 
the PINK1 gene are all localised in or very near to its kinase 
domain, indicating a loss of function of this kinase domain as 
the culprit. Indeed, this is the kinase domain that phosphory-
lates Parkin in the mitophagy process and mutant varieties in 
this region fail to recruit Parkin (Song et al., 2013).
It is still debated whether Parkin and PINK1 deficien-
cy-mediated mitophagy impairment is sufficient to cause a 
PD phenotype. Indeed, Parkin and PINK1 are not the only 
means of mitophagy regulation. For example, the MUL1 
pathway can compensate for Parkin/PINK1 deficiency and 
removing both pathways aggravates the phenotype beyond 
the loss of a single pathway (Yun et al., 2014). Additionally, 
in mouse myocytes, Parkin can still be recruited to defective 
mitochondria in the absence of PINK1 (Kubli et al., 2015). 
However, specifically under high ATP demand, PINK1 KO 
F I G U R E  1  Simplified schematic representation of the toxic cycle underlying the substantia nigra pars compacta degeneration seen in PD. An 
increase in α-syn levels can induce α-syn oligomer formation. These oligomers permeabilise cell and vesicle membranes, causing accumulation of 
cytosolic dopamine and Ca2+, where the latter further promotes dopamine production. Cytosolic dopamine auto-oxidises into dopamine quinones, 
forming reactive oxygen species (ROS) in the process, which in turn promotes α-syn oligomer formation. Dopamine quinones stabilise α-syn 
oligomers as well as forming adducts with α-syn monomers, which block chaperone-mediated autophagy (CMA). Subsequently, CMA-mediated 
degradation of α-syn (and other CMA substrates) is impaired leading to further α-syn accumulation. The factors in this positive feedback cycle all 
contribute to cellular stress, protein, DNA and lipid damage, eventually leading to cell death
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does lead to mitochondrial issues. Subsequently, cytosolic 
Ca2+ levels rise as Ca2+ export pumps require a lot of ATP. 
The SNc and LC coincidentally have a high ATP demand 
due to their intrinsic pacemaking activity; thus, PINK1 de-
ficiency could potentially lead to issues in these areas spe-
cifically (Heeman et al., 2011). Additionally, the increase in 
cytosolic Ca2+ positively regulates catecholamine production 
(Mosharov et al., 2009), while the ATP deficiency can impair 
VMAT2 functioning, both of which cause an increase in cy-
tosolic dopamine levels.
Aside from its role in mitochondrial quality control, 
Parkin has other interesting functions with potential impli-
cations in PD. For example, Parkin can protect against dopa-
mine toxicity and apoptosis in human neuroblastoma cells. It 
specifically suppressed dopamine-induced ROS production 
and subsequent apoptosis, while having no effect on the con-
sequences of ROS in general. Moreover, this protective effect 
was not seen in Parkin with PD-linked mutations (Jiang, Ren, 
Zhao, & Feng, 2004). Lastly, in a rat model for PD express-
ing aggregation-prone A30P α-syn, Parkin overexpression 
protected from neurodegeneration while mediating an in-
crease in α-syn aggregation (Lo Bianco et al., 2004). This is 
in line with the notion that α-syn aggregates are potentially 
protective when compared to small oligomeric species. Thus, 
Parkin could potentially antagonise the oligomer-stabilising 
effect of cytosolic dopamine.
Taken together, Parkin and PINK1 work closely together 
in regulating mitochondrial quality control, an effect that is 
dependent on Parkin functionality. A loss of Parkin function 
due to mutation or lack of activation by the upstream PINK1 
may lead to mitochondrial issues, increased oxidative stress 
and Ca2+ disturbances that the SNc and LC are specifically 
vulnerable to due to their high energy demand. These con-
ditions subsequently favour dopamine oxidation and α-syn 
accumulation, while Parkin's protective effects against dopa-
mine toxicity and its ability to deal with the consequences of 
pathogenic α-syn accumulation are impaired.
5 |  FAMILIAL PD—DJ-1
Several mutations in the PARK7 gene, encoding DJ-1, have 
been shown to cause recessive, early-onset PD (Bonifati et 
al., 2003; Malgieri & Eliezer, 2008) that may be associ-
ated with Lewy body accumulation (Taipa et al., 2016). 
Similar to Parkin and PINK1 mutations, DJ-1 homozygo-
sity is accompanied by a 100% disease penetrance with 
an early onset (Schulte & Gasser, 2011). DJ-1 is a small 
protein with a myriad of functions, including ROS scav-
enging (Andres-Mateos et al., 2007), metal ion binding 
(Björkblom et al., 2013), chaperone activity (Shendelman, 
Jonason, Martinat, Leete, & Abeliovich, 2004), CMA 
regulation(Xu et al., 2017) and transcriptional regulation. 
The PD-related mutations in DJ-1 cause a loss of struc-
ture, increased degradation and/or decreased dimerisation 
(Malgieri & Eliezer, 2008). Together with heterozygote 
susceptibility to sporadic PD, this also indicates a loss of 
function being the underlying cause. Due to its wide range 
of functions, it has proven very difficult to elucidate how 
it mediates specific the catecholaminergic neuronal degen-
eration leading to PD. However, there are several connec-
tions that can be made to mechanisms involved in PD.
One such mechanism is that DJ-1 protects against ROS 
through direct interaction with mitochondria. DJ-1 deficiency 
leads to altered mitochondrial morphology, likely causing 
slight alterations in mitophagy and a subsequent increase of 
ROS production (McCoy & Cookson, 2011; Trempe & Fon, 
2013). This effect can be rescued by Parkin and/or PINK1 
overexpression, as these respond to depolarised mitochon-
dria and regulate their subsequent clearance (Trempe & 
Fon, 2013). Moreover, DJ-1 can be oxidised at Cys-106 to 
function as a ROS scavenger (Andres-Mateos et al., 2007), 
while DJ-1 levels also increase in response to oxidative stress 
caused by dopamine to suppress ROS accumulation (Lev et 
al., 2013). Thus, a lack of DJ-1 can contribute to increased 
oxidative stress.
Additionally, DJ-1 interacts with α-syn and can in-
fluence the aggregation process of pathological α-syn. 
DJ-1 can directly inhibit the early aggregation steps of 
α-syn by acting as a redox-dependent molecular chaper-
one. Oxidising conditions make proteins, including α-syn, 
more prone to aggregate; thus, it makes sense to have a 
condition-dependent defence mechanism. The chaperone 
activity of DJ-1 requires oxidation of Cys-53 caused by 
the presence of ROS. DJ-1 was shown to suppress the for-
mation of α-syn oligomers, and subsequently their toxic 
effects (Shendelman et al., 2004). Additionally, DJ-1 defi-
ciency caused a decrease in LAMP2A expression, the re-
ceptor required for CMA-mediated α-syn degradation, and 
subsequent α-syn accumulation (Xu et al., 2017). Taken 
together, the lack of DJ-1 may contribute to α-syn aggrega-
tion through impaired chaperoning activity and decreased 
α-syn degradation.
Most intriguing though are the effects of DJ-1 deficiency 
on dopamine homeostasis. In Dictyostelium discoideum, 
DJ-1 KD did not result in the expected mitochondrial dys-
function-related phenotype. However, decreased DJ-1 ex-
pression caused a slower phagocytosis rate, while increased 
expression caused a higher phagocytosis rate (Chen et al., 
2017). Interestingly, this effect has been found to extend to 
neurons, where DJ-1 KO in primary cultured mouse neu-
rons severely impaired synaptic vesicle endocytosis. The 
effect was completely rescued after transfection with WT 
DJ-1, but not after transfection with PD-related mutant 
varieties of DJ-1. Moreover, the exocytosis process was 
unaffected by DJ-1 KO. Altogether, this caused a severe 
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depletion of the pre-synaptic vesicle pool upon neuronal 
stimulation (Kyung et al., 2018). Additionally, DJ-1 reg-
ulates the expression of VMAT2, the sole transporter re-
sponsible for sequestering dopamine inside pre-synaptic 
vesicles. DJ-1 overexpression boosts VMAT2 expression, 
while DJ-1 KD resulted in decreased VMAT2 expression. 
As DJ-1 levels increase under (dopamine-induced) oxi-
dative stress, this likely serves as a feedback mechanism 
where DJ-1 increases VMAT2 in response to increased 
cytosolic dopamine levels (Lev et al., 2013). Conversely, 
DJ-1 depletion can severely impair the dopamine storage 
ability of dopaminergic neurons.
Interestingly, DJ-1 KO alone does not lead to a neurode-
generative phenotype in mice, while it leads to early-onset 
PD in humans. DJ-1-deficient mice do exhibit alterations 
in dopamine metabolism compared to WT mice. Young 
DJ-1-deficient mice show an increase in dopamine turn-
over accompanied by increased ROS production. In aged 
DJ-1-deficient mice, this turnover is decreased compared 
to WT, while there is an increase in dopamine re-uptake 
via DAT, causing an accumulation of striatal dopamine 
(Raman et al., 2013). While cytosolic dopamine normally 
interacts with and inhibits TH as a feedback mechanism, 
the presence of oxidised dopamine species can increase TH 
activity on the long term (Acheson, Zigmond, & Stricker, 
1980). Although there are signs of cellular damage, DJ-1 
KO mice do not show signs of neurodegeneration and cell 
death (Raman et al., 2013). The discrepancy is likely due 
to human SNc neurons having higher overall and oxidised 
dopamine levels than their mouse counterparts, making 
them more susceptible to dopamine oxidation. This is re-
flected by neuromelanin formation in the human SNc, 
while mice lack this pigmentation (Burbulla et al., 2017). 
Experimentally increasing dopamine levels in WT mouse 
iPSC have no significant effect on oxidised dopamine lev-
els. However, doing the same thing in DJ-1 KO mouse iPSC 
caused a dramatic increase in oxidised dopamine levels. In 
vivo experiments in mice also showed that combining DJ-1 
KO with l-Dopa treatment caused SNc neurodegeneration 
with α-syn aggregation. Additionally, they demonstrated 
that combining DJ-1 deficiency with aggregation-prone 
α-syn A53T showed more severe neurodegeneration and 
increased oxidised dopamine levels than in α-syn A53T 
mice with functional DJ-1 (Burbulla et al., 2017). This 
corroborates that aggregating α-syn can increase oxidised 
dopamine levels and vice versa.
Taken together, DJ-1 deficiency can cause major dis-
turbances in dopamine storage through depletion of the 
pre-synaptic vesicle pool and decreased VMAT2 ex-
pression. In addition, in mice it mediates dopamine ac-
cumulation at a later age through increased dopamine 
re-uptake. Lastly, DJ-1 deficiency leads also to increased 
oxidative stress, which it could normally protect against. 
Combined, this provides the perfect conditions for dopa-
mine oxidation and quinone formation, which in turn can 
mediate α-syn aggregation and cellular damage leading to 
neurodegeneration.
6 |  DISCUSSION
Genetic cases of a disease can offer critical insight into the 
disease mechanism and pathways involved. However, genes 
related to familial variants of PD are often involved in mul-
tiple cellular functions and pathways, making it difficult 
to distinguish exactly what functionality underlies the PD-
related symptoms. Due to the highly similar degeneration of 
the SNc and LC between sporadic and familial PD, it is likely 
that the mechanism involved in these areas is the same as 
in sporadic PD, although the trigger may be different. The 
recessive familial PD gene variants of Parkin, PINK1 and 
DJ-1 are shown to be capable of causing disruptions in both 
dopamine and Ca2+ homeostasis, leading to dopamine qui-
none formation, mitochondrial issues and related oxidative 
stress. In turn, these conditions trigger α-syn aggregation and 
subsequently set in motion a positive feedback cycle towards 
neuronal death. In contrast to sporadic PD, α-syn aggrega-
tion should start in the SNc and LC in these specific genetic 
cases, as it is triggered by conditions unique to these areas. 
It would be very interesting to see Braak staging of α-syn 
propagation in these cases specifically if possible. Taken to-
gether, the mutant varieties of PD-related genes, although op-
erating in different pathways, may all disrupt at least one of 
the three key players central to the neurodegeneration seen in 
PD, leading to disease. However, this review only discussed 
the known recessive variants and it remains to be elucidated 
whether similar connections can be made for the autosomal 
dominant familial variants of PD.
The disease mechanisms of DJ-1 and Parkin dysfunction 
specifically could also have implications for PD in general. 
DJ-1 forms conjugates with dopamine quinones, with modi-
fications by dopamine on both Cys-53 and Cys-106. The for-
mer causes the formation of covalent dimers, while the latter 
makes DJ-1 more thermodynamically unstable and causes 
the formation of dopamine-modified high molecular weight 
species (Girotto et al., 2012). Normally, oxidation of these 
specific Cys residues is required for DJ-1 to function as a 
chaperone and ROS scavenger, respectively (Andres-Mateos 
et al., 2007; Shendelman et al., 2004). Although the exact 
consequences of these dopamine quinone interactions remain 
to be elucidated, it almost certainly interferes with its normal 
functioning. Thus, the protective functions of DJ-1 may also 
be impaired to some extent in PD cases unrelated to DJ-1 
mutation. Additionally, dopamine quinones can covalently 
bind Parkin, forming adducts that functionally inactivate it 
and cause Parkin to cluster together in insoluble aggregates 
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(LaVoie et al., 2005). This presents another potential loop, 
where dopamine toxicity can disable a mechanism that would 
normally protect against it. Taken together, in PD cases unre-
lated to DJ-1 or Parkin mutation, accumulation of dopamine 
quinones can cause impairment of these two proteins, which 
in turn could contribute to the degenerative process. This may 
provide an example why the distinction between familial and 
sporadic PD is not always clear-cut. Impairment of the same 
proteins may play a part in the disease process, even though 
dysfunction can arise at both the genetic and the protein level 
depending on the case.
Further research using model organisms is required to un-
ravel the specifics of the disease mechanisms and find the 
best therapeutic avenue per case. However, the importance 
of both dopamine and α-syn in SNc degeneration stands out, 
as it is seen in many model organisms for PD, including the 
commonly used MPTP-induced models. MPTP is a toxin that 
mediates specific PD-like neurodegeneration, with promi-
nent neuronal death in the SNc and LC. Since its discovery in 
the 70s, it has been widely used to replicate the consequences 
of PD-related neurodegeneration in model organisms, in ad-
dition to providing evidence that PD symptoms can occur 
due to environmental toxin exposure. MPTP makes use of 
dopamine transporters like DAT and VMAT2 to cross mem-
branes. Once in the cell, it exerts its toxic effects by blocking 
complex 1 of the mitochondrial respiration chain, causing 
mitochondrial dysfunction, high levels of ROS and eventu-
ally cell death (Langston, 2017). Indeed, mitochondrial defi-
cits are also observed in Parkin/PINK1 deficiency, in which 
it causes disturbances that the SNc and LC are particularly 
vulnerable to. Interestingly, in MPTP-induced models, other 
dopaminergic areas like the VTA are relatively spared, just as 
is seen in PD. Moreover, prolonged exposure to MPTP causes 
α-syn accumulation, indicating that the selective sensitivity 
to MPTP may involve similar mechanisms implicated in PD 
(Meredith & Rademacher, 2011). This is supported by the 
finding that α-syn KO mice are resistant to MPTP toxicity 
(Dauer et al., 2002), and increased cytosolic dopamine levels 
may enhance MPTP toxicity in mice. However, the latter is 
difficult to assess as increased dopamine levels were induced 
through dopamine transporter manipulation (Lohr et al., 
2016; Masoud et al., 2015; Takahashi et al., 1997). As MPTP 
makes use of these same transporters, this would potentially 
alter cellular MPTP levels as well, yielding inaccurate re-
sults. However, it would be interesting to see whether MPTP 
exposure after l-Dopa treatment also enhances MPTP tox-
icity, as this would likely have a lesser effect on transporter 
presence. Altogether, the specificity of MPTP-mediated tox-
icity cannot be attributed only to its specific use of dopamine 
transporters but may also involve the presence of α-syn and 
dopamine. This provides additional insight into how MPTP-
induced models emulate PD-related degeneration so accu-
rately. Additionally, it indicates that modulating the presence 
of α-syn and dopamine could indeed be effective in prevent-
ing degeneration of the SNc.
Research into specific familial variants of PD has been 
particularly difficult because animal models often do not ex-
hibit any PD-related symptoms. Recent findings in a DJ-1 
KO mouse model suggest that this may be because the human 
SNc contains significantly higher amounts of cytosolic do-
pamine than any model organism (Burbulla et al., 2017). 
Indeed, it is becoming clear that in familial PD variants like 
Parkin, PINK1 and DJ-1, α-syn aggregation with subse-
quent neurodegeneration is likely a secondary effect that is 
induced by disruption of dopamine and Ca2+ homeostasis. 
Due to the lower dopamine levels in these model organisms, 
it is conceivable that there is not enough dopamine to sig-
nificantly disrupt, resulting in a lack of phenotype. Elevating 
dopamine levels through l-Dopa administration in the case 
of these DJ-1 KO mice caused them to develop PD-like phe-
notype, which either condition alone was unable to accom-
plish. Thus, model organisms in general may not accurately 
reflect the human situation in terms of SNc dopamine ho-
meostasis, resulting in potential disease mechanisms being 
overlooked. Indeed, Parkin KO mice also show no clear PD 
phenotype on their own, which could very well be due to the 
same reason. The mechanism of Parkin deficiency-related 
degeneration is partly dependent on the dopamine toxicity it 
causes through mitochondrial issues and increased cytosolic 
dopamine levels (Mosharov et al., 2009). It is likely that in 
mice, this effect is not dramatic enough to trigger excessive 
dopamine toxicity due to the lower dopamine levels in this 
species. Subsequently, the adverse effects on α-syn, for ex-
ample, remain absent, and neurodegeneration does not occur. 
Taken together, increasing neuronal dopamine levels in con-
cert with a familial PD mutation may be required to achieve 
a correct phenotype in models for other genetic PD variants 
as well. Indeed, the conditions for developing PD are almost 
exclusively seen in humans. To understand the complex in-
teractions underlying the degenerative process, future studies 
should be aimed at updating PD models where necessary to 
accurately reflect the human situation. Interestingly, if cyto-
solic dopamine levels can be the determining factor whether 
neurodegeneration occurs in the presence of DJ-1 mutation, 
it may present an interesting potential therapeutic avenue for 
these cases.
Elucidating a degenerative mechanism may open new av-
enues for therapeutic intervention. It now seems that the most 
prominent degeneration in sporadic PD as well as familial 
PD variants involves α-syn accumulation, cytosolic catechol-
amines and Ca2+. Each can be the potential trigger, depend-
ing on the underlying disease variant, and all can exacerbate 
each other's toxic effects. Although there is a central mecha-
nism, each PD-related mutation can disrupt this mechanism 
via a different route. In terms of therapy, this means that 
the required treatment will likely need to be case-specific, 
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dependent on the underlying genetic variant and pathway 
affected. Given the many genetic varieties underlying PD, 
many different therapeutic strategies may have to be devel-
oped. On the other hand, the central degenerative mechanism 
also provides a potential bottleneck where all different path-
ways intersect. It has been suggested that modulation of one 
or more of α-syn, cytosolic catecholamines and Ca2+ could 
protect SNc and LC neurons from PD-related degeneration 
in general (Post et al., 2018), given that these are the primary 
contributors to toxicity. When the disruption of either of these 
is caused by an underlying genetic mutation, modulation of 
this specific component affected may prove sufficient to pre-
vent or delay symptomatic disease onset by preventing exces-
sive toxicity in the SNc and LC. This could prove particularly 
effective in variants where the pathology originates in these 
areas. For example, if the primary disease mechanism of 
DJ-1 mutation-related degeneration is the formation of dopa-
mine quinones through disruption of dopamine homeostasis, 
preventing excessive dopamine oxidation by modulating cy-
tosolic dopamine levels could suffice as a therapy. Moreover, 
this same therapy may work in other variants as well, albeit 
by slowing down disease progression or preventing a selec-
tion of symptoms. In sporadic PD where α-syn is the primary 
culprit, it may prove less effective as the pathological spread 
of α-syn continues and will still cause further degeneration, 
dementia and other (non-motor) symptoms; however, it may 
slow degeneration of the areas where catecholamines play 
a contributing role. Taken together, a central degenerative 
mechanism provides an opportunity for a general therapeutic 
strategy. Nevertheless, the effectiveness may be dependent on 
the underlying cause, and in certain variants, case-dependent 
treatment may be necessary.
Although there are promising results regarding the mech-
anisms underlying PD, the main challenge for application of 
therapeutic measures, however, is diagnostics. By the time 
patients exhibit the motor symptoms by which they are di-
agnosed, they have already lost over 50% of their SNc neu-
rons, and it is not possible to regain what has been lost. 
Additionally, upon extensive neuronal death, other factors 
come in to play that start contributing to the degenerative 
process, complicating the potential for therapeutic measures 
even further and making them less effective. For example, 
disruption of the basal ganglia–thalamo–cortical motor loop 
due to SNc degeneration causes increased activity of the sub-
thalamic nucleus, which feeds back to the SNc. The increase 
in activity mediates increased glutamate release at the SNc, 
potentially leading to excitotoxicity that further contributes to 
neuronal degeneration (Rodriguez, Obeso, & Olanow, 1998). 
Additionally, the death of neuromelanin-containing neurons 
causes neuromelanin, and thus iron and catecholamine qui-
nones, to be released in the extracellular environment. This 
triggers microglia and causes a state of chronic neuroinflam-
mation that results in further neuronal damage (Zhang et al., 
2011). For effective treatment of PD, and neurodegenerative 
diseases in general, therapeutic measures should ideally be 
taken before the onset of degeneration, which makes early 
diagnosis critical. While timely diagnosis of sporadic PD is a 
major hurdle due to a lack of symptoms and disease markers, 
it is possible for variants caused by known genetic mutations, 
like Parkin, PINK1 or DJ-1. In these cases, therapies aimed 
at modulating catecholamine oxidation, cytosolic-free Ca2+ 
levels and/or α-syn accumulation may be able to prevent or at 
least delay disease onset as they could be applied before the 
onset of degeneration.
It is very likely that due to the many disease-related genes 
and pathways, there is no single cause for PD. However, this 
review shows that familial variants related to Parkin, PINK1 
and DJ-1 can set in motion a chain of events that triggers the 
same degenerative mechanism that is present in sporadic PD. 
The aberrant interactions between α-syn, cytosolic catechol-
amines and Ca2+ ions, where disruption of one will disrupt 
the others, can set in motion a vicious toxic cycle leading 
to neurodegeneration. Moreover, this mechanism is specific 
to the SNc and LC, which explains why these areas are so 
selectively and severely affected in sporadic and familial 
cases alike. While there are many genetic triggers that may 
require as many different therapies to prevent the disease, the 
convergence of pathways on a single mechanism also pro-
vides us with a strategic bottleneck for potential interven-
tion in disease progression. The usage of accurate models 
is extremely important to elucidate this topic, as there is ev-
idence that most model organisms do not have high enough 
cytosolic catecholamine levels to reflect the human situation. 
However, future research utilising solid model systems can 
provide us with new potential therapeutic avenues to pursue.
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